Rose BioSolutions
Rockville, MD · Memphis, TN · Keele, United Kingdom
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
64.0
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (19)
✓ Press (4)
○ EMA GMP
○ MHRA GMP
Quick Facts: Rose BioSolutions
- Signal Score
- 64.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Rockville, MD · Memphis, TN · Keele, United Kingdom
- Website
- https://rosebiosolutions.com/
- Modalities
- AAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Rose BioSolutions
Rose BioSolutions is a cell and gene therapy CDMO, formed when GI Partners acquired Charles River's CDMO and Cell Solutions businesses (completed May 2026). Sites: Rockville, MD (viral vectors, formerly Vigene), Memphis, TN (cell therapy, formerly Cognate) and Keele, UK (plasmid DNA, formerly Cobra). Website: https://rosebiosolutions.com/
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Adenoviral, Plasmid, Cell Therapy, CAR-T
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
19 SEC filings with industry mentions on record (shown, not scored)
SEC Filings19 with industry mentions (not scored)
Private company
Financial assessment: 60.0/100
Capacity
68.0
3 manufacturing sites
Broad modality coverage (6 modalities)
Sites: Rockville, MD, Memphis, TN, Keele, United Kingdom
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
Press Signals4 articles (not scored)
3 manufacturing sites
Broad modality coverage (6 modalities)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source:
public careers pages
· Checked Oct 31, 2026
Financial Intelligence
"Item 7.01 Regulation FD Disclosure: On September 24, 2026, in connection with its Investor Day, Charles River Laboratories International, Inc. (the “Company”) issued a press release that, among other things, discusses its business strategy, reaffirms its full-year 2026 guidance, and provides its long-term financial targets through 2030. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein."
"crl-20260627
0001100682
12/26
2026
Q2
false
P11Y
365
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
crl:segment
xbrli:pure
0001100682
2025-12-28
2026-06-27
0001100682
2026-07-25
0001100682
us-gaap:ServiceMember
2026-03-29
2026-06-27
0001100682
us-gaap:ServiceMember
2025-03-30
2025-06-28
0001100682
us-gaap:ServiceMember
2025-12-28
2026-06-27
0001100682
us-gaap:ServiceMember
2024-12-29
2025-06-28
0001100682
us-gaap:ProductMember
2026-03-29
2026-06-27
0001100682
us-gaap:ProductMember
2025-03-30
"
"In May 2026, the Company sold the contract development and manufacturing products and services (CDMO) business, reported in the Manufacturing segment."
"Divestiture of CDMO and Cell Solutions
On May 6, 2026, the Company sold its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for net cash paid to the buyer of $
12.4
million, net of costs to sell and subject to certain customary closing adjustments."
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
"Item 5.02 Departure of Directors or Certain Officers; Election of: Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers."
"Item 5.07 Submission of Matters to a Vote of Security Holders: At the Company’s Annual Meeting, the following proposals were"
"crl-20260328
0001100682
12/26
2026
Q1
false
P11Y
333
824
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
crl:segment
xbrli:pure
iso4217:EUR
0001100682
2025-12-28
2026-03-28
0001100682
2026-04-24
0001100682
us-gaap:ServiceMember
2025-12-28
2026-03-28
0001100682
us-gaap:ServiceMember
2024-12-29
2025-03-29
0001100682
us-gaap:ProductMember
2025-12-28
2026-03-28
0001100682
us-gaap:ProductMember
2024-12-29
2025-03-29
0001100682
2024-12-29
2025-03-29
0001100682
2026-03-28
0001100682
2025-12-27
000110"
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Divestiture of CDMO and Cell Solutions
On May 6, 2026, the Company completed the sale of its CDMO and Cell Solutions businesses (CDMO and Cell Solutions Divestiture) to GI Partners (GI) for future contingent performance-based payments up to $
50.0
million, subject to certain customary closing adjustments."
"Item 2.02 Results of Operations and Financial Condition: The following information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing."
"Planned Divestiture of CDMO and Cell Solutions Businesses
On February 25, 2026, Charles River Laboratories International, Inc."
"(the “Company”) announced that it has signed a definitive agreement to divest its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners, primarily for future, contingent performance-based payments."
"The CDMO business provides services related to the production of advanced therapies for gene-modified cell therapies, as well as gene therapies including viral vectors and plasmid DNA; and the Cell Solutions business provides human-derived cellular materials used in the development and production of cell therapies."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the nine months ended September 27, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the six months ended June 28, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"The decrease in intangible assets for the three months ended March 29, 2025 related primarily to the accelerated amortization of certain CDMO client relationships in the Biologics Solutions reporting unit, normal amortization over the useful lives, and a divestiture of a site in the DSA reportable segment."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our client base includes major global pharmaceutical companies, many biotechnology companies;
agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies
around the world."
"We have extensive expertise in the discovery of clinical candidates and in the design, execution and reporting of safety assessment studies for numerous types of therapeutic modalities, including cell and gene therapies, small and large molecule pharmaceuticals, industrial and agricultural chemicals, vaccines, consumer products, veterinary medicines, biocides and medical devices."
"Biologics Solutions is comprised of both our Biologics Testing Solutions business, which provides specialized testing of biologics frequently outsourced by global pharmaceutical and biotechnology companies, and our contract development and manufacturing products and services (“CDMO”) business, which provides comprehensive contract development and manufacturing solutions for cell and gene therapies."
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Our Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
"Attorney’s Office for the Southern District of Florida that a Cambodian non-human primate supplier and two Cambodian officials had been criminally charged in connection with illegally importing non-human primates into the United States; client demand, particularly future demand for drug discovery and development products and services, including the outsourcing of these services; our expectations with respect to our ability to meet financial targets; our expectations regarding stock repurchases, "
"The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides
in vitro
(non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO)."
"Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world."
Source: SEC EDGAR · Retrieved Nov 01, 2026
Company Signals 4 articles
Company announcements, not verified evidence. They do not change any score.
GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions - PR Newswire
Moonshot AI's $2b valuation, Strooer's PE interest, Lambda's credit facility - Axios
FirstWord Lists – The 20 largest pharma M&A deals - FirstWord Pharma
GI Partners Completes Acquisition Of Charles River Laboratories’ CDMO And Cell Solutions Businesses - Pulse 2.0
Frequently Asked Questions About Rose BioSolutions
What is Rose BioSolutions's CDMO Signal Score?
Rose BioSolutions has a Signal Score of 64/100, based on quality, operations, financial stability, and capacity data.
Evaluating Rose BioSolutions for a manufacturing program?
Use the free AI matchmaker to compare Rose BioSolutions against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 78.5
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 76.2
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
Signal Score: 79.5
Viral Vectors, AAV, Lentiviral, Adenoviral, HPAPIs, Small Molecules, Peptides, BioCatalysis, Chromatography, Cell Therapy
OmniaBio
Hamilton, ON
Signal Score: 61.5
AAV, Lentiviral, CAR-T, Cell Therapy
Compare Rose BioSolutions with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.